{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T04:28:40Z","timestamp":1788496120104,"version":"build-2803163510"},"reference-count":166,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2011,7,29]],"date-time":"2011-07-29T00:00:00Z","timestamp":1311897600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/3.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>MUC1 is a membrane-tethered mucin expressed on the ductal cell surface of glandular epithelial cells. Loss of polarization, overexpression and aberrant glycosylation of MUC1 in mucosal inflammation and in adenocarcinomas induces humoral immune responses to the mucin. MUC1 IgG responses have been associated with a benefit in survival in patients with breast, lung, pancreatic, ovarian and gastric carcinomas. Antibodies bound to the mucin may curb tumor progression by restoring cell-cell interactions altered by tumor-associated MUC1, thus preventing metastatic dissemination, as well as counteracting the immune suppression exerted by the molecule. Furthermore, anti-MUC1 antibodies are capable of effecting tumor cell killing by antibody-dependent cell-mediated cytotoxicity. Although cytotoxic T cells are indispensable to achieve anti-tumor responses in advanced disease, abs to tumor-associated antigens are ideally suited to address minimal residual disease and may be sufficient to exert adequate immune surveillance in an adjuvant setting, destroying tumor cells as they arise or maintaining occult disease in an equilibrium state. Initial evaluation of MUC1 peptide\/glycopeptide mono and polyvalent vaccines has shown them to be immunogenic and safe; anti-tumor responses are scarce. Progress in carbohydrate synthesis has yielded a number of sophisticated substrates that include MUC1 glycopeptide epitopes that are at present in preclinical testing. Adjuvant vaccination with MUC1 glycopeptide polyvalent vaccines that induce strong humoral responses may prevent recurrence of disease in patients with early stage carcinomas. Furthermore, prophylactic immunotherapy targeting MUC1 may be a strategy to strengthen immune surveillance and prevent disease in subjects at hereditary high risk of breast, ovarian and colon cancer.<\/jats:p>","DOI":"10.3390\/cancers3033073","type":"journal-article","created":{"date-parts":[[2011,7,29]],"date-time":"2011-07-29T10:15:46Z","timestamp":1311934546000},"page":"3073-3103","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":31,"title":["Natural and Induced Humoral Responses to MUC1"],"prefix":"10.3390","volume":"3","author":[{"given":"Silvia","family":"Von Mensdorff-Pouilly","sequence":"first","affiliation":[{"name":"Department of Obstetrics and Gynecology, VU University Medical Center, De Boelelaan 1117, Amsterdam 1081 HV, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Moreno","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, VU University Medical Center, De Boelelaan 1117, Amsterdam 1081 HV, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ren\u00e9 H. M.","family":"Verheijen","sequence":"additional","affiliation":[{"name":"Department of Woman & Baby, Division of Surgical & Oncological Gynaecology, University Medical Center Utrecht, Heidelberglaan 100, Utrecht 3508 GA, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2011,7,29]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1146\/annurev.physiol.70.113006.100659","article-title":"Structure and function of the cell surface (tethered) mucins","volume":"70","author":"Hattrup","year":"2008","journal-title":"Annu. Rev. Physiol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1038\/nrc2761","article-title":"Mucins in cancer: Function, prognosis and therapy","volume":"9","author":"Kufe","year":"2009","journal-title":"Nat. Rev. Cancer"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.biochi.2009.09.018","article-title":"The membrane-bound mucins: From cell signaling to transcriptional regulation and expression in epithelial cancers","volume":"92","author":"Jonckheere","year":"2010","journal-title":"Biochimie"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1002\/ijc.2910280104","article-title":"Monoclonal antibodies to epithelium-specific components of the human milk fat globule membrane: Production and reaction with cells in culture","volume":"28","author":"Peterson","year":"1981","journal-title":"Int. J. Cancer"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1159\/000056500","article-title":"Summary report on the ISOBM TD-4 workshop: Analysis of 56 monoclonal antbodies against the MUC1 mucin","volume":"19","author":"Price","year":"1998","journal-title":"Tumor Biol."},{"key":"ref_6","first-page":"55","article-title":"Tissue and tumor distribution of human polymorphic epithelial mucin","volume":"11-12","author":"Zotter","year":"1988","journal-title":"Cancer Rev."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1002\/ijc.2910430620","article-title":"A core protein epitope of the polymorphic epithelial mucin detected by the monoclonal antibody SM-3 is selectively exposed in a range of primary carcinomas","volume":"43","author":"Girling","year":"1989","journal-title":"Int. J. Cancer"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1111\/j.1365-2559.2010.03667.x","article-title":"Expression of aberrantly glycosylated Mucin-1 in ovarian cancer","volume":"57","author":"Frings","year":"2010","journal-title":"Histopathology"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1093\/ajcp\/111.6.741","article-title":"MUC1 expression in hematopoietic tissues","volume":"111","author":"Dent","year":"1999","journal-title":"Am. J. Clin. Pathol."},{"key":"ref_10","first-page":"6846","article-title":"The epithelial tumor antigen MUC1 is expressed in hematological malignancies and is recognized by MUC1-specific cytotoxic T-lymphocytes","volume":"61","author":"Brossart","year":"2001","journal-title":"Cancer Res."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1136\/jcp.54.12.933","article-title":"MUC1 (EMA) is preferentially expressed by ALK positive anaplastic large cell lymphoma, in the normally glycosylated or only partly hypoglycosylated form","volume":"54","author":"Snijdewint","year":"2001","journal-title":"J. Clin. Pathol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1111\/j.1365-2141.2006.06331.x","article-title":"Cancer specific Mucin-1 glycoforms are expressed on multiple myeloma","volume":"135","author":"Cloosen","year":"2006","journal-title":"Br. J. Haematol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1016\/0046-8177(95)90146-9","article-title":"Prognostic significance of MUC1 epithelial mucin expression in breast cancer","volume":"26","author":"McGuckin","year":"1995","journal-title":"Hum. Pathol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1002\/(SICI)1096-9896(199711)183:3<311::AID-PATH917>3.0.CO;2-2","article-title":"Expression of MUC1 and MUC2 mucins in epithelial ovarian tumors","volume":"183","author":"Dong","year":"1997","journal-title":"J. Pathol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1038\/sj.bjc.6690355","article-title":"Expression of MUC1 mucins inversely correlated with postsurgical survival of renal cell carcinoma patients","volume":"80","author":"Fujita","year":"1999","journal-title":"Br. J. Cancer"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.1002\/1097-0142(20010601)91:11<1973::AID-CNCR1222>3.0.CO;2-A","article-title":"The importance of MUC1 cellular localization in patients with breast carcinoma: An immunohistologic study of 71 patients and review of the literature","volume":"91","author":"Rahn","year":"2001","journal-title":"Cancer"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1007\/s00535-003-1224-6","article-title":"Increased expression of MUC1 in advanced pancreatic cancer","volume":"38","author":"Hinoda","year":"2003","journal-title":"J. Gastroenterol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1093\/clinchem\/43.4.585","article-title":"Clinical and technical evaluation of ACS BR serum assay of MUC1 gene-derived glycoprotein in breast cancer, and comparison with CA 15-3 assays","volume":"43","author":"Bon","year":"1997","journal-title":"Clin. Chem."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.1016\/j.cca.2010.08.039","article-title":"CA 15-3: Uses and limitation as a biomarker for breast cancer","volume":"411","author":"Duffy","year":"2010","journal-title":"Clin. Chim. Acta"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"12820","DOI":"10.1016\/S0021-9258(18)37632-4","article-title":"A highly immunogenic region of a human polymorphic epithelial mucin expressed by carcinomas is made up of tandem repeats","volume":"263","author":"Gendler","year":"1988","journal-title":"J. Biol. Chem."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1038\/328082a0","article-title":"The human tumour-associated epithelial mucins are coded by an expressed hypervariable gene locus PUM","volume":"328","author":"Swallow","year":"1987","journal-title":"Nature"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"15286","DOI":"10.1016\/S0021-9258(18)77254-2","article-title":"Molecular cloning and expression of human tumor-associated polymorphic epithelial mucin","volume":"265","author":"Gendler","year":"1990","journal-title":"J. Biol. Chem."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"33325","DOI":"10.1074\/jbc.271.52.33325","article-title":"Comparison of O-linked carbohydrate chains in MUC1-mucin from normal breast epithelial cell lines and breast carcinoma cell lines. Demonstration of simpler and fewer glycan chains in tumor cells","volume":"271","author":"Lloyd","year":"1996","journal-title":"J. Biol. Chem."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"27764","DOI":"10.1074\/jbc.M103187200","article-title":"Identification and topology of variant sequences within individual repeat domains of the human epithelial tumor mucin MUC1","volume":"276","author":"Engelmann","year":"2001","journal-title":"J. Biol. Chem."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1007\/s00439-003-1011-8","article-title":"Hypervariability of the membrane-associated mucin and cancer marker MUC1","volume":"113","author":"Fowler","year":"2003","journal-title":"Hum. Genet."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"307","DOI":"10.2174\/138920306778018034","article-title":"Immunology of O-glycosylated proteins: Approaches to the design of a MUC1 glycopeptide-based tumor vaccine","volume":"7","author":"Hanisch","year":"2006","journal-title":"Curr. Protein Pept. Sci."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1159\/000086956","article-title":"What makes MUC1 a tumor antigen?","volume":"26","author":"Karsten","year":"2005","journal-title":"Tumor Biol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1002\/(SICI)1097-0215(19970926)73:1<50::AID-IJC9>3.0.CO;2-0","article-title":"Selection of tumor antigens as targets for immune attack using immune-histochemistry: II. Blood group-related antigens","volume":"73","author":"Zhang","year":"1997","journal-title":"Int. J. Cancer"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1007\/s001090050144","article-title":"Immunoreactive T and Tn epitopes in cancer diagnosis, prognosis, and immunotherapy","volume":"75","author":"Springer","year":"1997","journal-title":"J. Mol. Med."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"137","DOI":"10.4161\/hv.2941","article-title":"Cancer vaccines targeting carbohydrate antigens","volume":"2","author":"Livingston","year":"2006","journal-title":"Hum. Vaccin"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1186\/bcr2577","article-title":"Tumour-associated carbohydrate antigens in breast cancer","volume":"12","author":"Cazet","year":"2010","journal-title":"Breast Cancer Res."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1042\/bst0230826","article-title":"MUC1, endometrium and embryo implantation","volume":"23","author":"Aplin","year":"1995","journal-title":"Biochem. Soc. Trans."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1042\/bst0230822","article-title":"Involvement of the cell-surface bound mucin, episialin\/MUC1, in progression of human carcinomas","volume":"23","author":"Hilkens","year":"1995","journal-title":"Biochem. Soc. Trans."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1093\/intimm\/dxh219","article-title":"MUC1 mucin-mediated regulation of human T cells","volume":"17","author":"Agrawal","year":"2005","journal-title":"Int. Immunol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","article-title":"Hallmarks of cancer: The next generation","volume":"144","author":"Hanahan","year":"2011","journal-title":"Cell"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1038\/nm0198-043","article-title":"Cancer-associated MUC1 mucin inhibits human T-cell proliferation, which is reversible by IL-2","volume":"4","author":"Agrawal","year":"1998","journal-title":"Nat. Med."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1002\/(SICI)1097-0215(19990827)82:5<721::AID-IJC16>3.0.CO;2-N","article-title":"Soluble MUC1 secreted by human epithelial cancer cells mediate immune suppression by blocking T-cell activation","volume":"82","author":"Chan","year":"1999","journal-title":"Int. J. Cancer"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/j.tcb.2006.07.006","article-title":"Cell surface-associated mucins in signal transduction","volume":"16","author":"Singh","year":"2006","journal-title":"Trends Cell Biol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"5663","DOI":"10.1038\/onc.2010.334","article-title":"Oncogenic function of the MUC1 receptor subunit in gene regulation","volume":"29","author":"Kufe","year":"2010","journal-title":"Oncogene"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"5667","DOI":"10.1038\/onc.2010.327","article-title":"The reactive tumor microenvironment: MUC1 signaling directly reprograms transcription of CTGF","volume":"29","author":"Behrens","year":"2010","journal-title":"Oncogene"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"2833","DOI":"10.1158\/0008-5472.CAN-08-4513","article-title":"MUC1-induced transcriptional programs associated with tumorigenesis predict outcome in breast and lung cancer","volume":"69","author":"Khodarev","year":"2009","journal-title":"Cancer Res."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1177\/172460080001500413","article-title":"Human MUC1 mucin: A multifaceted glycoprotein","volume":"15","author":"Snijdewint","year":"2000","journal-title":"Int. J. Biol. Markers"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1159\/000053903","article-title":"Maternal serum Ca125 and Ca15-3 antigen levels in normal and pathological pregnancy","volume":"16","author":"Bon","year":"2001","journal-title":"Fetal. Diagn. Ther."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1159\/000217871","article-title":"Factors effecting the measurement of tumor-associated MUC1 mucins in serum","volume":"15","author":"McGuckin","year":"1994","journal-title":"Tumor Biol."},{"key":"ref_45","first-page":"2257","article-title":"Does pregnancy immunize against breast cancer?","volume":"55","author":"Agrawal","year":"1995","journal-title":"Cancer Res."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1023\/A:1012220902991","article-title":"Humoral immune response induced by the protein core of MUC1 Mucin in pregnant and healthy women","volume":"69","author":"Croce","year":"2001","journal-title":"Breast Cancer Res. Treat."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1053\/gast.2002.34157","article-title":"Altered expression and allelic association of the hypervariable membrane mucin MUC1 in Helicobacter pylori gastritis","volume":"123","author":"Vinall","year":"2002","journal-title":"Gastroenterology"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1002\/(SICI)1097-0215(19991022)84:5<466::AID-IJC3>3.0.CO;2-#","article-title":"Aberrant expression of MUC1 mucin in ductal hyperplasia and ductal carcinoma in situ of the breast","volume":"84","author":"Mommers","year":"1999","journal-title":"Int. J. Cancer"},{"key":"ref_49","first-page":"2457","article-title":"Human B-cell immune response to the polymorphic epithelial mucin","volume":"53","author":"Rughetti","year":"1993","journal-title":"Cancer Res."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"3693","DOI":"10.4049\/jimmunol.151.7.3693","article-title":"Cytotoxic T cells from ovarian malignant tumors can recognize polymorphic epithelial mucin core peptides","volume":"151","author":"Ioannides","year":"1993","journal-title":"J. Immunol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1007\/s002620050531","article-title":"Isolation of MUC1-primed B-lymphocytes from tumor draining lymph nodes using immunomagentic beads","volume":"47","author":"Petrarca","year":"1999","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1007\/BF01520296","article-title":"Expression of monoclonal-antibody-defined antigens in fractions isolated from human breast carcinomas and patients'serum","volume":"40","author":"Croce","year":"1995","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1038\/bjc.1995.436","article-title":"Polymorphic epithelial mucin (MUC-1)-containing circulating immune complexes in carcinoma patients","volume":"72","author":"Gourevitch","year":"1995","journal-title":"Br. J. Cancer"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1023\/A:1026110417294","article-title":"Tissue and serum MUC1 mucin detection in breast cancer patients","volume":"81","author":"Croce","year":"2003","journal-title":"Breast Cancer Res. Treat."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1186\/1471-2407-6-253","article-title":"MUC1 expression and anti-MUC1 serum immune response in head and neck squamous cell carcinoma (HNSCC): A multivariate analysis","volume":"6","author":"Rabassa","year":"2006","journal-title":"BMC Cancer"},{"key":"ref_56","first-page":"1325","article-title":"Humoral immune response to polymorphic epithelial mucin (MUC-1) in patients with benign and malignant breast tumours","volume":"32A","author":"Gourevitch","year":"1996","journal-title":"Eur. J. Cancer"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/0165-2478(93)90086-H","article-title":"Detection of a circulating antibody against a peptide epitope on a mucin core protein, MUC1, in ulcerative colitis","volume":"35","author":"Hinoda","year":"1993","journal-title":"Immunol. Lett."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1007\/PL00009971","article-title":"Circulating autoantibodies against purified colonic mucin in ulcerative colitis","volume":"35","author":"Takaishi","year":"2000","journal-title":"J. Gastroenterol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1159\/000051907","article-title":"Mucins and immune reactions to mucins in ulcerative colitis","volume":"63","author":"Hayashi","year":"2001","journal-title":"Digestion"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1080\/08820130601109727","article-title":"Impact of Helicobacter pylori infection on the humoral immune response to MUC1 peptide in patients with chronic gastric diseases and gastric cancer","volume":"36","author":"Klaamas","year":"2007","journal-title":"Immunol. Investig."},{"key":"ref_61","first-page":"2856","article-title":"Humoral immunity against a tandem repeat epitope of human mucin MUC-1 in sera from breast, pancreatic, and colon cancer patients","volume":"54","author":"Kotera","year":"1994","journal-title":"Cancer Res."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1007\/s002620050484","article-title":"Antibodies reactive with the protein core of MUC1 mucin are present in ovarian cancer patients and healthy women","volume":"46","author":"Richards","year":"1998","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1159\/000030006","article-title":"An enzyme-linked immunosorbent assay for the measurement of circulating antibodies to polymorphic epithelial mucin (MUC1)","volume":"19","author":"Gourevitch","year":"1998","journal-title":"Tumor Biol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"3147","DOI":"10.1182\/blood.V96.9.3147","article-title":"Elevated soluble MUC1 levels and decreased anti-MUC1 antibody levels in patients with multiple myeloma","volume":"96","author":"Treon","year":"2000","journal-title":"Blood"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1200\/JCO.2000.18.3.574","article-title":"Survival in early breast cancer patients is favorably influenced by a natural humoral immune response to polymorphic epithelial mucin","volume":"18","author":"Verstraeten","year":"2000","journal-title":"J. Clin. Oncol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1159\/000132566","article-title":"A combination of serum tumor markers identifies high-risk patients with early-stage squamous cervical cancer","volume":"29","author":"Davelaar","year":"2008","journal-title":"Tumor Biol."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1007\/s005350050096","article-title":"Detection of circulating anti-MUC1 mucin core protein antibodies in patients with colorectal cancer","volume":"33","author":"Nakamura","year":"1998","journal-title":"J. Gastroenterol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.molimm.2008.12.025","article-title":"Humoral immune response to abnormal MUC1 in subjects with colorectal adenoma and cancer","volume":"47","author":"Silk","year":"2009","journal-title":"Mol. Immunol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1093\/annonc\/mdm007","article-title":"Autoantibodies in breast cancer: Their use as an aid to early diagnosis","volume":"18","author":"Chapman","year":"2007","journal-title":"Ann. Oncol."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1021\/pr700818f","article-title":"Humoral immunity directed against tumor-associated antigens as potential biomarkers for the early diagnosis of cancer","volume":"7","author":"Lu","year":"2008","journal-title":"J. Proteome Res."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"982425","DOI":"10.1155\/2011\/982425","article-title":"Autoantibodies to tailor-made panels of tumor-associated antigens in breast carcinoma","volume":"2011","author":"Piura","year":"2011","journal-title":"J. Oncol."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"4442","DOI":"10.1158\/0008-5472.CAN-07-5607","article-title":"Immunoglobulin allotypes influence antibody responses to mucin 1 in patients with gastric cancer","volume":"68","author":"Pandey","year":"2008","journal-title":"Cancer Res."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"2025","DOI":"10.1007\/s00262-009-0709-4","article-title":"A genetic variant of immunoglobulin gamma2 is strongly associated with immunity to mucin 1 in patients with breast cancer","volume":"58","author":"Pandey","year":"2009","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1164\/ajrccm.161.2.9905028","article-title":"Natural autoantibody to MUC1 is a prognostic indicator for non-small cell lung cancer","volume":"161","author":"Hirasawa","year":"2000","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1002\/ijc.10801","article-title":"Circulating anti-MUC1 IgG antibodies as a favorable prognostic factor for pancreatic cancer","volume":"103","author":"Hamanaka","year":"2003","journal-title":"Int. J. Cancer"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1080\/02841860601055441","article-title":"Humoral immune response to MUC1 and to the Thomsen-Friedenreich (TF) glycotope in patients with gastric cancer: Relation to survival","volume":"46","author":"Kurtenkov","year":"2007","journal-title":"Acta Oncol."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"1848","DOI":"10.1002\/ijc.23725","article-title":"Induction of IgG antibodies to MUC1 and survival in patients with epithelial ovarian cancer","volume":"123","author":"Oei","year":"2008","journal-title":"Int. J. Cancer"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1158\/1055-9965.EPI-05-0035","article-title":"Conditions associated with antibodies against the tumor-associated antigen MUC1 and their relationship to risk for ovarian cancer","volume":"14","author":"Cramer","year":"2005","journal-title":"Cancer Epidemiol. Biomark. Prev."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1007\/s10552-010-9546-1","article-title":"Mumps and ovarian cancer: Modern interpretation of an historic association","volume":"21","author":"Cramer","year":"2010","journal-title":"Cancer Causes Control"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"1556","DOI":"10.1016\/j.ejca.2007.04.007","article-title":"Humoral immune responses to MUC1 in women with a BRCA1 or BRCA2 mutation","volume":"43","author":"Hermsen","year":"2007","journal-title":"Eur. J. Cancer"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1002\/(SICI)1097-0215(20000601)86:5<702::AID-IJC16>3.0.CO;2-1","article-title":"Reactivity of natural and induced human antibodies to MUC1 mucin with MUC1 peptides and n-acetylgalactosamine (GalNAc) peptides","volume":"86","author":"Petrakou","year":"2000","journal-title":"Int. J. Cancer"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"1860","DOI":"10.1002\/ijc.25778","article-title":"Seromic profiling of colorectal cancer patients with novel glycopeptide microarray","volume":"128","author":"Pedersen","year":"2011","journal-title":"Int. J. Cancer"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1373\/clinchem.2009.136333","article-title":"Sweetening the pot: Adding glycosylation to the biomarker discovery equation","volume":"56","author":"Drake","year":"2010","journal-title":"Clin. Chem."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"R25","DOI":"10.1186\/bcr2841","article-title":"Autoantibodies to aberrantly glycosylated MUC1 in early stage breast cancer are associated with a better prognosis","volume":"13","author":"Blixt","year":"2011","journal-title":"Breast Cancer Res."},{"key":"ref_85","unstructured":"Burchell, J. (2011). Can auto-antibodies to aberrant glycoforms of MUC1 be used as prognostic and diagnostic markers?, 11th Workshop on Mucins in Health and Disease."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"2783","DOI":"10.1172\/JCI119825","article-title":"Antibody and T cell responses of patients with adenocarcinoma immunized with mannan-MUC1 fusion protein","volume":"100","author":"Karanikas","year":"1997","journal-title":"J. Clin. Invest."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1023\/A:1018521217276","article-title":"Natural human anti-Gal alpha(1,3)Gal antibodies react with human mucin peptides","volume":"14","author":"Sandrin","year":"1997","journal-title":"Glycoconj. J."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1586\/erv.10.51","article-title":"Vaccine-induced antibody responses in patients with carcinoma","volume":"9","year":"2010","journal-title":"Expert Rev. Vaccines"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1097\/00002371-200203000-00001","article-title":"Immunologic monitoring of cancer vaccine therapy: Results of a workshop sponsored by the Society for Biological Therapy","volume":"25","author":"Keilholz","year":"2002","journal-title":"J. Immunother."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1159\/000056503","article-title":"\u2018Epitope fingerprinting\u2019 using overlapping 20-mer peptides of the MUC1 tandem repeat sequence","volume":"19","author":"Schol","year":"1998","journal-title":"Tumor Biol."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.1016\/S0959-8049(96)00254-7","article-title":"Human antibodies against the polymorphic epithelial mucin in ovarian cancer patients recognise a novel sequence in the tandem repeat region","volume":"32A","author":"Petrarca","year":"1996","journal-title":"Eur. J. Cancer"},{"key":"ref_92","first-page":"4324","article-title":"Human single-chain Fv antibodies to MUC1 core peptide selected from phage display libraries recognize unique epitopes and predominantly bind adenocarcinoma","volume":"58","author":"Henderikx","year":"1998","journal-title":"Cancer Res."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1111\/j.1399-3011.2005.00297.x","article-title":"Malignancy-induced autoimmunity to MUC1: Initial antibody characterization","volume":"66","author":"Graves","year":"2005","journal-title":"J. Pept. Res."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.molimm.2008.09.032","article-title":"Identification of O-glycosylated decapeptides within the MUC1 repeat domain as potential MHC class I (A2) binding epitopes","volume":"47","author":"Ninkovic","year":"2009","journal-title":"Mol. Immunol."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1093\/glycob\/cwi058","article-title":"Sequence-variant repeats of MUC1 show higher conformational flexibility, are less densely O-glycosylated and induce differential B lymphocyte responses","volume":"15","author":"Kinarsky","year":"2005","journal-title":"Glycobiology"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1084\/jem.20020493","article-title":"Complex carbohydrates are not removed during processing of glycoproteins by dendritic cells: Processing of tumor antigen MUC1 glycopeptides for presentation to major histocompatibility complex class II-restricted T cells","volume":"196","author":"Vlad","year":"2002","journal-title":"J. Exp. Med."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"3242","DOI":"10.1002\/eji.200324189","article-title":"O-Linked glycans control glycoprotein processing by antigen-presenting cells: A biochemical approach to the molecular aspects of MUC1 processing by dendritic cells","volume":"33","author":"Hanisch","year":"2003","journal-title":"Eur. J. Immunol."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"2380","DOI":"10.4049\/jimmunol.179.4.2380","article-title":"O-glycosylated human MUC1 repeats are processed in vitro by immunoproteasomes","volume":"179","author":"Ninkovic","year":"2007","journal-title":"J. Immunol."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1083\/jcb.129.1.255","article-title":"Episialin (MUC1) overexpression inhibits integrin-mediated cell adhesion to extracellular matrix components","volume":"129","author":"Wesseling","year":"1995","journal-title":"J. Cell Biol."},{"key":"ref_100","first-page":"359","article-title":"Cell membrane-associated mucins and their adhesion-modulating property","volume":"17","author":"Hilkens","year":"1992","journal-title":"TIBS"},{"key":"ref_101","first-page":"2318","article-title":"Suppression of cellular aggregation by high levels of episialin","volume":"52","author":"Ligtenberg","year":"1992","journal-title":"Cancer Res."},{"key":"ref_102","first-page":"2014","article-title":"Decreased MUC1 expression induces E-Cadherin-mediated cell adhesion of breast cancer cell lines","volume":"58","author":"Kondo","year":"1998","journal-title":"Cancer Res."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1002\/ijc.1554","article-title":"Overexpression of MUC1 reconfigures the binding properties of tumor cells","volume":"94","author":"McDermott","year":"2001","journal-title":"Int. J. Cancer"},{"key":"ref_104","first-page":"4244","article-title":"The breast mucin MUC1 as a novel adhesion ligand for endothelial intercellular adhesion molecule 1 in breast cancer","volume":"56","author":"Regimbald","year":"1996","journal-title":"Cancer Res."},{"key":"ref_105","first-page":"5577","article-title":"MUC1 synthetic peptide inhibition of intercellular adhesion molecule -1 and MUC1 binding requires six tandem repeats","volume":"58","author":"Kam","year":"1998","journal-title":"Cancer Res."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1146\/annurev-pathol-011110-130224","article-title":"Mechanisms of leukocyte transendothelial migration","volume":"6","author":"Muller","year":"2011","journal-title":"Annu. Rev. Pathol."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1023\/A:1011039013134","article-title":"MUC1 in carcinoma-host interactions","volume":"17","author":"Irimura","year":"2000","journal-title":"Glycoconj. J."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1007\/s12038-010-0073-8","article-title":"Glycan changes: Cancer metastasis and anti-cancer vaccines","volume":"35","author":"Li","year":"2010","journal-title":"J. Biosci."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1002\/ijc.2910570621","article-title":"E selectin binding by pancreatic tumor cells is inhibited by cancer sera","volume":"57","author":"Sawada","year":"1994","journal-title":"Int. J. Cancer"},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1002\/(SICI)1097-4644(19960315)60:4<538::AID-JCB10>3.0.CO;2-D","article-title":"Secreted MUC1 mucins lacking their cytoplasmic part and carrying sialyl-Lewis a and x epitopes from a tumour cell line and sera of colon carcinoma patients can inhibit HL-60 leukocyte adhesion to E-selecting-expressing endothelial cells","volume":"60","author":"Zhang","year":"1996","journal-title":"J. Cell Biochem."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"10222","DOI":"10.1158\/0008-5472.CAN-06-2483","article-title":"MUC1 is a counter-receptor for myelin-associated glycoprotein (Siglec-4a) and their interaction contributes to adhesion in pancreatic cancer perineural invasion","volume":"67","author":"Swanson","year":"2007","journal-title":"Cancer Res."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1074\/jbc.M606862200","article-title":"Galectin-3 interaction with Thomsen-Friedenreich disaccharide on cancer-associated MUC1 causes increased cancer cell endothelial adhesion","volume":"282","author":"Yu","year":"2007","journal-title":"J. Biol. Chem."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1186\/1476-4598-9-154","article-title":"Interaction between circulating galectin-3 and cancer-associated MUC1 enhances tumour cell homotypic aggregation and prevents anoikis","volume":"9","author":"Zhao","year":"2010","journal-title":"Mol. Cancer"},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1159\/000051917","article-title":"MUC1 mucin core protein binds to the domain 1 of ICAM-1","volume":"63","author":"Hayashi","year":"2001","journal-title":"Digestion"},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1038\/346425a0","article-title":"Adhesion receptors of the immune system","volume":"346","author":"Springer","year":"1990","journal-title":"Nature"},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1038\/nm0198-043","article-title":"Cancer-associated MUC1 mucin inhibits human T-cell proliferation, which is reversible by IL-2","volume":"4","author":"Agrawal","year":"1998","journal-title":"Nat. Med."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1002\/(SICI)1097-0215(19990827)82:5<721::AID-IJC16>3.0.CO;2-N","article-title":"Soluble MUC1 secreted by human epithelial cancer cells mediate immune suppression by blocking T-cell activation","volume":"82","author":"Chan","year":"1999","journal-title":"Int. J. Cancer"},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1007\/s002620050547","article-title":"Cellular and humoral responses to MUC1 mucin and tandem-repeat peptides in ovarian cancer patients and controls","volume":"48","author":"Snijdewint","year":"1999","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1046\/j.1365-2567.1999.00827.x","article-title":"Macrophage-tumour cell interactions: Identification of MUC1 on breast cancer cells as potential counter-receptors for the macrophage-restricted receptor, sialoadhesin","volume":"98","author":"Nath","year":"1999","journal-title":"Immunology"},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1111\/j.1600-065X.2008.00607.x","article-title":"The Yin-Yang of tumor-associated macrophages in neoplastic progression and immune surveillance","volume":"222","author":"Allavena","year":"2008","journal-title":"Immunol. Rev."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1038\/nri2744","article-title":"Monoclonal antibodies: Versatile platforms for cancer immunotherapy","volume":"10","author":"Weiner","year":"2010","journal-title":"Nat. Rev. Immunol."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1182\/blood.V99.3.754","article-title":"Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene","volume":"99","author":"Cartron","year":"2002","journal-title":"Blood"},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1158\/0008-5472.CAN-10-4222","article-title":"Antibody-dependent cell cytotoxicity synapses form in mice during tumor-specific antibody immunotherapy","volume":"71","author":"Hubert","year":"2011","journal-title":"Cancer Res."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1002\/ijc.1286","article-title":"Antibody-dependent cell-mediated cytotoxicity can be induced by MUC1 peptide vaccination of breast cancer patients","volume":"93","author":"Snijdewint","year":"2001","journal-title":"Int. J. Cancer"},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.canlet.2007.06.016","article-title":"High level of MUC1 in serum of ovarian and breast cancer patients inhibits huHMFG-1 dependent cell-mediated cytotoxicity (ADCC)","volume":"257","author":"Moreno","year":"2007","journal-title":"Cancer Lett."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.canlet.2008.06.028","article-title":"Toll-like receptor agonists and invariant natural killer T-cells enhance antibody-dependent cell-mediated cytotoxicity (ADCC)","volume":"272","author":"Moreno","year":"2008","journal-title":"Cancer Lett."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1586\/14760584.7.7.963","article-title":"Strategies used for MUC1 immunotherapy: Human clinical studies","volume":"7","author":"Tang","year":"2008","journal-title":"Expert Rev. Vaccines"},{"key":"ref_128","doi-asserted-by":"crossref","unstructured":"Scholl, S., Squiban, P., Bizouarne, N., Baudin, M., Acres, B., von Mensdorff-Pouilly, S., Shearer, M., Beuzeboc, P., Van Belle, S., and Uzielly, B. (2003). Metastatic Breast Tumour Regression Following Treatment by a Gene-Modified Vaccinia Virus Expressing MUC1 and IL-2. J. Biomed. Biotechnol., 194\u2013201.","DOI":"10.1155\/S111072430320704X"},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1586\/14760584.4.3.249","article-title":"Vaccination with BLP25 liposome vaccine to treat non-small cell lung and prostate cancers","volume":"4","author":"North","year":"2005","journal-title":"Expert Rev. Vaccines"},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1158\/1078-0432.CCR-05-1574","article-title":"Mannan-MUC1-pulsed dendritic cell immunotherapy: A phase I trial in patients with adenocarcinoma","volume":"12","author":"Loveland","year":"2006","journal-title":"Clin. Cancer Res."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1007\/0-387-27545-2_7","article-title":"Antibody inducing polyvalent cancer vaccines","volume":"123","author":"Ragupathi","year":"2005","journal-title":"Cancer Treat. Res."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"3520","DOI":"10.1158\/1078-0432.CCR-10-3126","article-title":"PROVENGE (Sipuleucel-T) in Prostate Cancer: The First FDA-Approved Therapeutic Cancer Vaccine","volume":"17","author":"Cheever","year":"2011","journal-title":"Clin. Cancer Res."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.1093\/annonc\/mdh472","article-title":"Phase I trial of a murine antibody to MUC1 in patients with metastatic cancer: Evidence for the activation of humoral and cellular antitumor immunity","volume":"15","author":"Bono","year":"2004","journal-title":"Ann. Oncol."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1038\/bjc.1993.349","article-title":"Adjuvant therapy of ovarian cancer with radioactive monoclonal antibody","volume":"68","author":"Hird","year":"1993","journal-title":"Br. J. Cancer"},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1016\/S0140-6736(88)92482-8","article-title":"Development of anti-idiotypic antibodies against tumour antigens and autoantigens in ovarian cancer patients treated intraperitoneally with mouse monoclonal antibodies","volume":"332","author":"Epenetos","year":"1988","journal-title":"Lancet"},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"3000","DOI":"10.1002\/1097-0142(19940615)73:12<3000::AID-CNCR2820731218>3.0.CO;2-G","article-title":"Activation of cellular immunity after intracavitary monoclonal antibody therapy of ovarian cancer","volume":"73","author":"Kosmas","year":"1994","journal-title":"Cancer"},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1200\/JCO.2005.02.5973","article-title":"Phase III trial of intraperitoneal therapy with yttrium-90-labeled HMFG1 murine monoclonal antibody in patients with epithelial ovarian cancer after a surgically defined complete remission","volume":"24","author":"Verheijen","year":"2006","journal-title":"J. Clin. Oncol."},{"key":"ref_138","first-page":"1283","article-title":"Phase-I study of synthetic muc1 peptides in breast-cancer","volume":"6","author":"Xing","year":"1995","journal-title":"Int. J. Oncol."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1002\/(SICI)1097-0215(19980610)76:6<817::AID-IJC9>3.0.CO;2-0","article-title":"Anti-MUC1 class I restricted CTLs in metastatic breast cancer patients immunized with a synthetic MUC1 peptide","volume":"76","author":"Reddish","year":"1998","journal-title":"Int. J. Cancer"},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1007\/s00262-004-0581-1","article-title":"Phase I study of a MUC1 vaccine composed of different doses of MUC1 peptide with SB-AS2 adjuvant in resected and locally advanced pancreatic cancer","volume":"54","author":"Ramanathan","year":"2005","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1097\/00002371-200103000-00012","article-title":"Mannan mucin-1 peptide immunization: influence of cyclophosphamide and the route of injection","volume":"24","author":"Karanikas","year":"2001","journal-title":"J. Immunother."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"R27","DOI":"10.1186\/bcr1505","article-title":"Pilot phase III immunotherapy study in early-stage breast cancer patients using oxidized mannan- MUC1 [ISRCTN71711835]","volume":"8","author":"Apostolopoulos","year":"2006","journal-title":"Breast Cancer Res."},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"1806","DOI":"10.1038\/sj.bjc.6990288","article-title":"Specificity analysis of sera from breast cancer patients vaccinated with MUC1-KLH plus QS-21","volume":"79","author":"Adluri","year":"1999","journal-title":"Br. J. Cancer"},{"key":"ref_144","first-page":"1693","article-title":"Vaccination of high-risk breast cancer patients with mucin-1 (MUC1) keyhole limpet hemocyanin conjugate plus QS-21","volume":"6","author":"Gilewski","year":"2000","journal-title":"Clin. Cancer Res."},{"key":"ref_145","unstructured":"Gilewski, G., Ragupathi, G., Bhuta, S., Clausen, H., Norton, L., Houghton, A., and Livingston, P. (2001). Preliminary Data: Vaccination with glycosylated mucin 1 (MUC-1)-keyhole limpet hemocyanin (KLH) conjugate plus the immunological adjuvant QS21 in breast cancer patients. Proc. Am. Soc. Clin. Oncol., 20, Abstract 1082."},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"4170","DOI":"10.1158\/1078-0432.CCR-06-2949","article-title":"Pilot study of a heptavalent vaccine-keyhole limpet hemocyanin conjugate plus QS21 in patients with epithelial ovarian, fallopian tube, or peritoneal cancer","volume":"13","author":"Sabbatini","year":"2007","journal-title":"Clin. Cancer Res."},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"5706","DOI":"10.4049\/jimmunol.174.9.5706","article-title":"Antibodies against tumor cell glycolipids and proteins, but not mucins, mediate complement-dependent cytotoxicity","volume":"174","author":"Ragupathi","year":"2005","journal-title":"J. Immunol."},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"1921","DOI":"10.1007\/s00262-007-0335-y","article-title":"A polyvalent vaccine for high-risk prostate patients: \u201cAre more antigens better?\u201d","volume":"56","author":"Slovin","year":"2007","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1586\/erv.09.95","article-title":"Synthetic carbohydrate-based anticancer vaccines: The Memorial Sloan-Kettering experience","volume":"8","author":"Zhu","year":"2009","journal-title":"Expert Rev. Vaccines"},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"9298","DOI":"10.1021\/ja901415s","article-title":"From synthesis to biologics: Preclinical data on a chemistry derived anticancer vaccine","volume":"131","author":"Zhu","year":"2009","journal-title":"J. Am. Chem. Soc."},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"2167","DOI":"10.1016\/j.tetlet.2009.02.138","article-title":"\u201cBiologic\u201d level structures through chemistry: A total synthesis of a unimolecular pentavalent MUCI glycopeptide construct","volume":"50","author":"Lee","year":"2009","journal-title":"Tetrahedron Lett."},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"7551","DOI":"10.1002\/anie.200902564","article-title":"A synthetic vaccine consisting of a tumor-associated sialyl-T(N)-MUC1 tandem-repeat glycopeptide and tetanus toxoid: Induction of a strong and highly selective immune response","volume":"48","author":"Kaiser","year":"2009","journal-title":"Angew Chem. Int. Ed. Engl."},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1002\/cbic.200800596","article-title":"Increasing the antigenicity of synthetic tumor-associated carbohydrate antigens by targeting Toll-like receptors","volume":"10","author":"Ingale","year":"2009","journal-title":"Chembiochem"},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"3688","DOI":"10.1002\/anie.201000462","article-title":"Fully synthetic vaccines consisting of tumor-associated MUC1 glycopeptides and a lipopeptide ligand of the Toll-like receptor 2","volume":"49","author":"Kaiser","year":"2010","journal-title":"Angew Chem. Int. Ed. Engl."},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"8498","DOI":"10.1002\/anie.201003810","article-title":"Synthetic antitumor vaccines from tetanus toxoid conjugates of MUC1 glycopeptides with the Thomsen-Friedenreich antigen and a fluorine-substituted analogue","volume":"49","author":"Kaiser","year":"2010","journal-title":"Angew Chem. Int. Ed. Engl."},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1002\/anie.201006115","article-title":"Self-adjuvanting multicomponent cancer vaccine candidates combining per-glycosylated MUC1 glycopeptides and the Toll-like receptor 2 agonist Pam3CysSer","volume":"50","author":"Wilkinson","year":"2011","journal-title":"Angew Chem. Int. Ed. Engl."},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"6396","DOI":"10.1002\/chem.201100217","article-title":"Towards a Fully Synthetic MUC1-Based Anticancer Vaccine: Efficient Conjugation of Glycopeptides with Mono-, Di-, and Tetravalent Lipopeptides Using Click Chemistry","volume":"17","author":"Cai","year":"2011","journal-title":"Chemistry"},{"key":"ref_158","first-page":"133","article-title":"Humoral and cellular immune responses: Independent forces or collaborators in the fight against cancer","volume":"2","author":"Reilly","year":"2001","journal-title":"Curr. Opin. Investig. Drugs"},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0065-2776(06)90001-7","article-title":"Cancer immunosurveillance and immunoediting: The roles of immunity in suppressing tumor development and shaping tumor immunogenicity","volume":"90","author":"Smyth","year":"2006","journal-title":"Adv. Immunol."},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1038\/nature06309","article-title":"Adaptive immunity maintains occult cancer in an equilibrium state","volume":"450","author":"Koebel","year":"2007","journal-title":"Nature"},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1038\/nrc1370","article-title":"Dissecting the metastatic cascade","volume":"4","author":"Pantel","year":"2004","journal-title":"Nat. Rev. Cancer"},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1002\/ijc.20655","article-title":"Persistence of bone marrow micrometastases in patients receiving adjuvant therapy for breast cancer: Results at 4 years","volume":"114","author":"Slade","year":"2005","journal-title":"Int. J. Cancer"},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1023\/A:1006697728855","article-title":"Autoimmune and antitumor consequences of antibodies against antigens shared by normal and malignant tissues","volume":"20","author":"Livingston","year":"2000","journal-title":"J. Clin. Immunol."},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.smim.2010.03.003","article-title":"Vaccines based on abnormal self-antigens as tumor-associated antigens: Immune regulation","volume":"22","author":"Farkas","year":"2010","journal-title":"Semin. Immunol."},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"B97","DOI":"10.1016\/j.vaccine.2007.06.067","article-title":"Lessons from randomized phase III studies with active cancer immunotherapies\u2014Outcomes from the 2006 Meeting of the Cancer Vaccine Consortium (CVC)","volume":"25","author":"Finke","year":"2007","journal-title":"Vaccine"},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/01.cji.0000211341.88835.ae","article-title":"Cancer Vaccine Clinical Trial Working Group. A clinical development paradigm for cancer vaccines and related biologics","volume":"30","author":"Hoos","year":"2007","journal-title":"J. Immunother."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/3\/3\/3073\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T21:56:55Z","timestamp":1760219815000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/3\/3\/3073"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,7,29]]},"references-count":166,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2011,9]]}},"alternative-id":["cancers3033073"],"URL":"https:\/\/doi.org\/10.3390\/cancers3033073","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,7,29]]}}}